Tricalcium phosphate and hydroxyapatite treatment for benign cavitary bone lesions: A prospective clinical trial.

Benign bone tumors are surgically treated by curettage and by filling the defect using bone grafts or bone substitutes, such as hydroxyapatite crystals and tricalcium phosphate. The tricalcium phosphate mixed with hydroxyapatite, although fragile, is a good alternative with good integration. Fifteen patients with benign bone lesions were randomized in two groups surgically treated by curettage and filling of the bone defect using allograft (7 cases) or a mixture of 35% tricalcium phosphate, with 60-85% pore volume, and 65% hydroxyapatite (8 cases). After the surgery, all patients were followed up every 3 weeks until 6 months, and then at 2 months interval until one year for the clinical and radiological assessment. The average age was 35.4 years (from 18 to 54) for the allograft group and 41 years (from 22 to 58) for the patients treated with bone substitute. Eight patients were male and seven female, with relatively equal distribution between both groups. The average bone defect was relatively equal: 14 cc (4-25 cc) for the allograft group and 15.1 cc (4-33 cc) for the ceramic group (P>0.1). During the follow-up, all the lesions gradually disappeared after 12 months, with a time of healing of 18.8 weeks (15-24 weeks) for the allograft group and 20.37 weeks (15-28) for the bone substitute group. There were no significant differences regarding the clinical status and the radiological assessment after 12 months. No patient required extra pain medication after 2 weeks. No complications have been recorded. The surgical treatment of small and medium sized lytic benign tumors has good results with both types of graft that were studied. Using tricalcium phosphate mixed with hydroxyapatite as bone substitute represents a good and low cost alternative, but it is a relatively fragile material with a slower time to integrate compared to the allograft.

[1]  P. Layrolle,et al.  Bone regeneration strategies with bone marrow stromal cells in orthopaedic surgery. , 2016, Current research in translational medicine.

[2]  S. Vukicevic,et al.  Biological aspects of segmental bone defects management , 2015, International Orthopaedics.

[3]  M. Zheng,et al.  The composite of hydroxyapatite and calcium sulphate: a review of preclinical evaluation and clinical applications , 2013, Expert review of medical devices.

[4]  M. Voor,et al.  Bone Healing Using a Bi-Phasic Ceramic Bone Substitute Demonstrated in Human Vertebroplasty and with Histology in a Rabbit Cancellous Bone Defect Model , 2012, Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences.

[5]  G. Calori,et al.  The use of bone-graft substitutes in large bone defects: any specific needs? , 2011, Injury.

[6]  J. Fischer,et al.  Bridging the gap: Bone marrow aspiration concentrate reduces autologous bone grafting in osseous defects , 2011, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[7]  S. Larsson Calcium Phosphates: What Is the Evidence? , 2010, Journal of orthopaedic trauma.

[8]  R. Grimer,et al.  Bone defects following curettage do not necessarily need augmentation , 2009, Acta orthopaedica.

[9]  G. Blunn,et al.  Composite Ceramic Bone Graft Substitute in the Treatment of Locally Aggressive Benign Bone Tumours , 2008, Journal of orthopaedic surgery.

[10]  Cato T Laurencin,et al.  Tissue engineering of bone: material and matrix considerations. , 2008, The Journal of bone and joint surgery. American volume.

[11]  N. Kastner,et al.  Painful soft-tissue reaction to injectable Norian SRS calcium phosphate cement after curettage of enchondromas. , 2003, The Journal of bone and joint surgery. British volume.

[12]  Søren Overgaard,et al.  No effect of Osteoset ® , a bone graft substitute, on bone healing in humans: A prospective randomized double-blind study , 2002, Acta orthopaedica Scandinavica.

[13]  M. Bohner Physical and chemical aspects of calcium phosphates used in spinal surgery , 2001, European Spine Journal.

[14]  G. Daculsi,et al.  Biphasic calcium phosphate/hydrosoluble polymer composites: a new concept for bone and dental substitution biomaterials. , 1999, Bone.

[15]  M. Chapman,et al.  Treatment of Acute Fractures with a Collagen-Calcium Phosphate Graft Material. A Randomized Clinical Trial*† , 1997, The Journal of bone and joint surgery. American volume.

[16]  Marc A. Asher,et al.  Iliac Crest Bone Graft Harvest Donor Site Morbidity: A Statistical Evaluation , 1995, Spine.

[17]  A. Levine,et al.  Chronic Donor Site Pain Complicating Bone Graft Harvesting From the Posterior Iliac Crest for Spinal Fusion , 1992, Spine.

[18]  B Kerebel,et al.  Transformation of biphasic calcium phosphate ceramics in vivo: ultrastructural and physicochemical characterization. , 1989, Journal of biomedical materials research.

[19]  V. Goldberg,et al.  Natural history of autografts and allografts. , 1987, Clinical orthopaedics and related research.

[20]  R. Marcove,et al.  Treatment of unicameral bone cyst. A follow-up study of one hundred seventy-five cases. , 1966, The Journal of bone and joint surgery. American volume.

[21]  T. Damron Use of 3D beta-tricalcium phosphate (Vitoss) scaffolds in repairing bone defects. , 2007, Nanomedicine.

[22]  O. Cornu,et al.  Bone substitutes in 2003: an overview. , 2003, Acta orthopaedica Belgica.